Микробиом кишечника и пробиотики: новый ключ к профилактике хронических заболеваний

Modern healthcare is very good at answering one question: what do we do now that this person is ill? The next focus should be why they became ill, and whether that could have been prevented. For many chronic diseases, particularly the ones rooted in lifestyle, that second question is where much of the leverage sits. Metabolic disorders are becoming more common. Allergic and immune conditions follow a similar path, and managing any of these for years costs far more than catching them early would. Chronic disease worldwide is projected to cost $47 trillion by 2030. Prevention costs a fraction of that. At this stage, it isn't just a health concern. It's turning into an economic one, too. If you look closely at the body, you can see it is already ready to stop many problems. The gut microbiome, modulated and maintained well, can contribute a great deal to it. The gut is often called the second brain, and roughly 70 percent of the immune system resides there. It plays a role in metabolism too, and in the inflammation that sits behind most chronic diseases. Antibiotics are overused. Diets have shifted toward low-fibre, processed food. City living adds its own pressure on top of that. Global antibiotic use has climbed 66 percent since 2000, and even a short course can suppress beneficial bacteria in the microbiome for months afterwards. Here's what makes this promising, though. Unlike genes, the microbiome can be changed. That single fact turns it from an interesting area of biology into something we can actually act on. Mapping the gut and its microbiome is no longer the difficult part with the advanced technologies at our disposal. The smart move that is required right now is what we must do with this information. Probiotics have proven to be one of the most efficient modes through which we can naturally redefine health through prevention. These probiotics are safe with less side effects and consumable by different demographics from children to old adults.  A 2024 overview in the United European Gastroenterology Journal, pooling 45 randomised controlled trials, found the evidence for probiotics strongest in ulcerative colitis, though results varied by condition. Probiotics also confer their benefits through the gut-immune axis like in the case of IBD, that extends their benefits beyond the gut for holistic health. Results depend on the exact strain and dose used because probiotics are not one single category with one shared benefit. A strain that works for one condition may do nothing for another. The mechanisms are becoming well understood. Certain strains reinforce the gut lining directly. Others work by calming an immune response that has become overactive. A different set produces compounds that fuel anti-inflammatory activity elsewhere in the body, and some strains simply take up space so harmful bacteria never get the chance to settle in. None of this is guesswork now. Each effect can be traced back to a specific strain. The next real gains in healthcare may not come from new drugs alone. They may come from managing the ecosystem already living inside us. The science is ready. The tools already exist. What's missing isn't possibility. It's the rigour and the will to put it into practice. (The author is MD & founder at Unique Biotech Limited)